About Corlieve Therapeutics

Corlieve Therapeutics was founded in November 2019 with a singular purpose of bringing novel therapeutic options to patients with severe neurological disorders.

The founders Richard Porter, Valerie Crepel and Christophe Mulle combine significant expertise in neuroscience research, epileptology and global drug discovery and development for neurological disorders, forming Corlieve with the support of international life science investors Kurma Partners and Idinvest Partners and leading AAV gene therapy company REGENXBIO.

Corlieve is now advancing its lead program in collaboration with Inserm, CNRS and REGENXBIO, and has licensed REGENXBIO’s NAV AAV9 technology.